By Adriano Marchese
Invivyd's stock fell sharply in pre-market trading Monday after U.S. regulators denied a request for its drug Pemgarda to be used in treating Covid-19 in more cases.
Shares traded 37% lower ahead of the morning bell at $1.12.
The commercial-stage biopharmaceutical company said its request to expand the existing emergency use authorization of the drug, also called pemivibart, to treat mild-to-moderate Covid-19 in more people was declined by the Food and Drug Administration.
Invivyd wanted to expand its use to adults and adolescents who have moderate-to-severe immune compromise due to certain medical conditions such as cancer and organ transplant, where other alternative Covid-19 treatment options weren't possible.
The recent denial by the FDA doesn't affect its existing emergency use authorization for pre-exposure prophylaxis of Covid-19 in certain immunocompromised patients, which still remains in effect, Invivyd said.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
February 24, 2025 07:48 ET (12:48 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.